|
TGR
BioSciences Pty Ltd
Overview
TGR BioSciences is a biotechnology company discovering novel bioactives,
developing therapies to enhance tissue growth and repair and providing
cell-based high-throughput screening services. TGR BioSciences was
established in 2001 as the means to build on the success, resources
and capabilities of the Cooperative Research Centre for Tissue Growth
and Repair (CRC-TGR), which unwound in 2002.
TGR works with external and internal strategic alliance partners
to discover and characterise novel bioactives for a broad range
of pharmaceutical, nutriceutical and veterinary applications. In
specific areas, notably gut and skin applications, TGR BioSciences
takes promising novel bioactivities through proof of concept studies
in validated animal models of disease.
TGR BioSciences offers its discovery and validation capability using
high throughput screening assays for cellular function on a collaborative
basis or as a fee-for-service via the Australian Proteome Analysis
Facility (APAF) .
Competitive
Advantages
Located in the Thebarton Biotechnology Precinct in South Australia,
TGR hosts the Adelaide Node of a Major National Research Facility,
the Australian Proteome Analysis Facility.
TGR and its extensive shareholder network of researchers have extensive
experience and expertise in the discovery, characterisation and
preclinical development of growth factors and other novel bioactives.
Technology
Discovery Services
TGR BioSciences’ discovery platform uses high-throughput
cell-based assays linked to non-denaturing protein separation technologies
(‘functional proteomics’) for screening of bioactivity
in natural products or compound libraries. The technology platform,
which is based on the sensitive detection of early cell signalling
pathway events, can be used to identify and characterise bioactivities
from complex mixtures (such as milk, serum, and tissue or cell extracts)
or to screen natural or chemical libraries on the basis of their
cellular functional activity.
Development
TGR BioSciences also develops and out-licenses novel therapies
for tissue growth and repair, particularly in gastrointestinal and
skin disorders, with applications in pharmaceutical, nutriceutical,
and veterinary markets. TGR has exclusive world-wide licence to
a portfolio of 6 patent families in the areas of gut and skin applications
of milk-derived growth factors.
Corporate
Alliances/Partnerships
Partners
Shareholders in TGR BioSciences include CRC-TGR members the Child
Health Research Institute, the Dairy Research & Development
Corporation, Flinders University and GroPep Ltd as well as new partners
Macquarie Research Ltd and the University of South Australia. TGR
BioSciences also is a consortium partner of the Australian Proteome
Analysis Facility along with Macquarie University, the University
of New South Wales and the University of Sydney
Partnering Opportunities
TGR BioSciences offers its advanced discovery and validation capabilities
on a collaborative basis or as a fee-for-service via the Australian
Proteome Analysis Facility. TGR BioSciences also partners in the
discovery, characterisation and preclinical development of growth
factors and other novel bioactives and in particular in the areas
of gut and skin applications.
Partnering Needs
TGR BioSciences seeks technology development and commercialisation
alliances in the field of tissue growth and repair, particularly
in gut and skin applications of milk-derived growth factors and
HTS screening alliances for drug discovery.
| Contact Person |
Dr Jay Czarnecki
|
 |
| Job Title |
Business Development |
| Address |
31 Dalgleish Street |
| City/Suburb |
Thebarton
SA 5031 Australia |
| Email |
jay.czarnecki@tgr-biosciences.com.au |
| Phone |
+61 8 8354 6173 |
| Fax |
+61 8 8354 6188 |
| Website |
www.tgr-biosciences.com.au |
back
|
